Sponsor Check › Person
Related person on Form D filings · address states as listed: LA, MA, GA, CO, TX · listed Apr 13, 2009 → May 22, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 12:09 AM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 12:09 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 12:09 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
1 of 22 offerings reports sales commissions totalling $3,000; 0 report finder's fees; 3 report proceeds to related persons totalling $258,410. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | May 22, 2026 D/A File 021-547107 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 14, 2025 D File 021-535069 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 7, 2024 D File 021-507011 | $0 | $0 | $144,000 (est.) $144,000 will go towards compensating the President and Chief Executive Officer. | None listed on this filing |
| EDGAR ↗ | Jun 15, 2020 D File 021-368961 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 30, 2019 D/A File 021-350179 | $3,000 | $0 | $0 | Witherspoon Partners BrokerCheck CRD 226591 ↗ |
| EDGAR ↗ | Dec 24, 2019 D File 021-356366 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2019 D File 021-344116 | $0 | $0 | $100,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 27, 2019 D/A File 021-289508 | $0 | $0 | $0 | Thornhill Securities, Inc. BrokerCheck CRD 22333 ↗ |
| EDGAR ↗ | Nov 7, 2017 D File 021-298243 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 25, 2016 D File 021-258127 | $0 | $0 | $14,410 Out of initial closing proceeds, Mr. Bartner was paid the amount above which represented interest accrued on a prior promissory note, the principal of which he agreed to roll-forward under the new Promissory Note Purchase Agreement & Credit Facility. | None listed on this filing |
| EDGAR ↗ | Sep 29, 2015 D/A File 021-232778 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 23, 2015 D/A File 021-227005 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 5, 2014 D File 021-212975 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 10, 2013 D File 021-207743 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 7, 2013 D/A File 021-190945 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 2, 2012 D File 021-177597 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 29, 2012 D File 021-174155 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 16, 2011 D File 021-164546 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 9, 2011 D File 021-160997 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 3, 2010 D/A File 021-124766 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 13, 2010 D/A File 021-115888 | $0 | $0 | $0 (est.) Proceeds from the offering will be used for general working capital. | None listed on this filing |
| EDGAR ↗ | Mar 10, 2010 D/A File 021-99589 | $0 | $0 | $0 Proceeds will be used for general working capital. | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Cancer Focus Fund II, LP | Director, Executive Officer Managing Member of the General Partner of the Issuer | May 22, 2026 | D/A | $250,000,000 similar: $500,000–$16,420,250 | $22,556,962 | 5 similar: 2–28 | No minimum reported similar: $5,000–$100,000 |
| EDGAR ↗ | Cancer Focus Fund II, LP | Director, Executive Officer Managing Member of the General Partner of the Issuer | May 23, 2025 | D | $250,000,000 similar: $500,000–$16,420,250 | $0 | 1 similar: 2–28 | No minimum reported similar: $5,000–$100,000 |
| EDGAR ↗ | A28 Therapeutics, Inc. | Director | Jan 14, 2025 | D | $1,900,000 similar: $1,100,015–$10,001,163 | $1,900,000 | 26 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | CALOSYN PHARMA, INC. | Executive Officer, Director Secretary | Mar 7, 2024 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $750,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lagniappe Labs, LLC | Executive Officer, Director LLC Manager | Jun 15, 2020 | D | $800,000 similar: $1,100,015–$10,001,163 | $534,056 | 13 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Dec 30, 2019 | D/A | $8,282,455 similar: $1,694,259–$16,000,000 | $6,128,235 | 70 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Cancer Focus Fund, LP | Executive Officer President, CEO and CFO of Focus Fund GP, LLC, the GP of the Issuer. | Dec 24, 2019 | D | $75,000,000 similar: $155,000–$5,250,000 | $49,700,000 | 19 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Oct 2, 2019 | D | $8,282,455 similar: $1,694,259–$16,000,000 | $6,128,235 | 70 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Esperance Pharmaceuticals, Inc | Director | Jul 12, 2019 | D | $1,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Congress Avenue Equity Armor, LP | Director Mr. Barrett is the managing member of Congress Avenue Holdings, LLC, the general partner of Congress Avenue GP, LP, the general partner of the issuer. | Jun 27, 2019 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,849,568 | 7 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Congress Avenue Equity Armor, LP | Director Mr. Barrett is the managing member of Congress Avenue Holdings, LLC, the general partner of Congress Avenue GP, LP, the general partner of the issuer. | Jun 28, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,600,000 | 5 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Lagniappe Labs, LLC | Executive Officer, Director | Nov 7, 2017 | D | $2,402,301 similar: $1,100,015–$10,001,163 | $1,652,301 | 12 similar: 2–14 | $100,000 similar: $5,000–$50,000 |
| EDGAR ↗ | Congress Avenue Equity Armor, LP | Director Mr. Barrett is the managing member of Congress Avenue Holdings, LLC, the general partner of Congress Avenue GP, LP, the general partner of the issuer. | Jun 27, 2017 | D | Indefinite similar: $155,000–$5,250,000 | $750,000 | 3 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | SOUTHEAST VENTURE HOLDINGS, LLC | Director Member and Director of the Manager | Feb 25, 2016 | D | $7,000,000 similar: $675,000–$10,000,000 | $2,310,000 | 7 similar: 1–12 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Sep 29, 2015 | D/A | $6,641,944 similar: $1,694,259–$16,000,000 | $4,511,399 | 19 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | MicroBiome Therapeutics, LLC | Director | Jun 23, 2015 | D/A | $1,800,000 similar: $829,831–$9,999,998 | $743,445 | 27 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Jan 23, 2015 | D | $4,488,523 similar: $1,694,259–$16,000,000 | $2,345,289 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | MicroBiome Therapeutics, LLC | Director | Oct 23, 2014 | D | $600,000 similar: $829,831–$9,999,998 | $30,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | NuPotential, Inc. | Director | Mar 5, 2014 | D | $375,000 similar: $1,694,259–$16,000,000 | $375,000 | 5 similar: 1–13 | $25,000 similar: $10,000–$55,000 |
| EDGAR ↗ | MicroBiome Therapeutics, LLC | Director | Dec 10, 2013 | D | $3,000,000 similar: $829,831–$9,999,998 | $1,265,131 | 19 similar: 2–15 | $20,000 similar: $10,000–$54,310 |
| EDGAR ↗ | NuPotential, Inc. | Director | Mar 7, 2013 | D/A | $350,000 | $350,000 | 2 | $35,000 |
| EDGAR ↗ | NuPotential, Inc. | Director | Jan 29, 2013 | D | $350,000 | $210,000 | 2 | $35,000 |
| EDGAR ↗ | MicroBiome Therapeutics, LLC | Director | May 2, 2012 | D | $1,500,000 | $1,109,985 | 15 | No minimum reported |
| EDGAR ↗ | CALOSYN PHARMA, INC. | Director | Feb 29, 2012 | D | $2,100,000 | $309,685 | 3 | No minimum reported |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Aug 16, 2011 | D | $4,505,800 | $3,505,644 | 8 | No minimum reported |
| EDGAR ↗ | Esperance Pharmaceuticals, Inc | Director | Jun 9, 2011 | D | $7,500,000 | $5,733,626 | 10 | No minimum reported |
| EDGAR ↗ | Esperance Pharmaceuticals, Inc | Director | May 3, 2010 | D/A | $9,000,000 | $9,000,000 | 3 | No minimum reported |
| EDGAR ↗ | Esperance Pharmaceuticals, Inc | Director | May 3, 2010 | D/A | $5,750,001 | $3,700,245 | 5 | No minimum reported |
| EDGAR ↗ | CALOSYN PHARMA, INC. | Director | Apr 13, 2010 | D/A | $3,265,653 | $1,863,392 | 5 | No minimum reported |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Mar 10, 2010 | D/A | $880,000 | $490,000 | 3 | No minimum reported |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | Nov 5, 2009 | D | $300,000 | $100,000 | 1 | No minimum reported |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | May 28, 2009 | D | $100,000 | $100,000 | 1 | No minimum reported |
| EDGAR ↗ | EMBERA NEUROTHERAPEUTICS, INC. | Director | May 28, 2009 | D | $500,000 | $300,000 | 5 | No minimum reported |
| EDGAR ↗ | CALOSYN PHARMA, INC. | Director | Apr 13, 2009 | D | $400,000 | $400,000 | 5 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (7 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as Ross Barrett. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
| Source | Filed | Form | Issuer | Amount offered (as reported) | Amount sold (as reported) | Matched on |
|---|---|---|---|---|---|---|
| EDGAR ↗ | Mar 2, 2026 File 020-36429 | Regulation Crowdfunding progress update (Form C-U) Progress update filed · deadline Feb 27, 2026 | CALOSYN PHARMA, INC. SHREVEPORT, LA | $20,000 target · $1,235,000 maximum via StartEngine Primary, LLC | Not reported on this form | signer name on this filing (Ross Pryor Barrett) + listed as a related person on Form D filings of the same issuer (CIK 1429819) · 85% |
| EDGAR ↗ | Dec 19, 2025 File 020-36429 | Regulation Crowdfunding offering — amendment (Form C/A) Amendment filed · deadline Feb 27, 2026 | Calosyn Pharma, Inc. Shreveport, LA | $20,000 target · $1,235,000 maximum via StartEngine Primary, LLC | Not reported on this form | signer name on this filing (Ross Pryor Barrett) + listed as a related person on Form D filings of the same issuer (CIK 1429819) · 85% |
| EDGAR ↗ | Sep 30, 2025 File 020-36429 | Regulation Crowdfunding offering (Form C) Offering filed · deadline Dec 29, 2025 | Calosyn Pharma, Inc. Shreveport, LA | $20,000 target · $1,235,000 maximum via StartEngine Primary, LLC | Not reported on this form | signer name on this filing (Ross Pryor Barrett) + listed as a related person on Form D filings of the same issuer (CIK 1429819) · 85% |
Amounts are as reported by the issuer on the form; Regulation Crowdfunding forms report a target and maximum, not sales. Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Ross Barrett appears on a new Form D, or when a court case or SEC action is matched to them. See plans →